Results 11 to 20 of about 2,270 (143)

Preoperative portal vein recanalization-transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation. [PDF]

open access: yesHepatol Commun, 2022
Patients with chronic, obliterative portal vein thrombosis may be converted to liver transplantation candidacy following portal vein recanalization‐transjugular intrahepatic portosystemic shunt (PVR‐TIPS). Long‐term survival outcomes of patients with chronic, obliterative portal vein thrombosis who undergo transplantation following PVR‐TIPS are similar
Talwar A   +15 more
europepmc   +2 more sources

Liver Transplantation Using Allografts With Hepatic Artery Injury During Procurement: A Propensity Score-Matched Analysis of Outcomes. [PDF]

open access: yesClin Transplant
ABSTRACT Background Hepatic artery (HA) injury during liver procurement is a significant concern in liver transplantation (LT). This study assessed its frequency and impact in deceased donor LT (DDLT). Methods This was a single‐center cohort study of adults who underwent DDLT from 2010 to 2019.
Jeune F   +6 more
europepmc   +2 more sources

Techniques for Management of Portal Vein Thrombosis during Liver Transplantation. [PDF]

open access: yesCase Rep Transplant, 2020
Portal vein thrombosis (PVT) poses a unique challenge in liver transplant. The management of PVT differs according to the extent of thrombosis. Anastomosis of a donor portal vein to a varix is a viable option when an adequate size varix is identified on preoperative imaging or intraoperatively.
Singh N, Washburn K, Black S, Schenk A.
europepmc   +2 more sources

Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies

open access: yesPediatric Discovery, Volume 1, Issue 2, September 2023., 2023
Abstract Glycogen storage disease type I (GSDI) is an inherited metabolic disorder characterized by a deficiency of enzymes or proteins involved in glycogenolysis and gluconeogenesis, resulting in excessive intracellular glycogen accumulation. While GSDI is classified into four different subtypes based on molecular genetic variants, GSDIa accounts for ...
Jiamin Zhong   +10 more
wiley   +1 more source

The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids

open access: yesJournal of Internal Medicine, Volume 294, Issue 3, Page 281-294, September 2023., 2023
Abstract The prevalence of cognitive dysfunction, dementia, and neurodegenerative disorders such as Alzheimer's disease (AD) is increasing in parallel with an aging population. Distinct types of chronic stress are thought to be instrumental in the development of cognitive impairment in central nervous system (CNS) disorders where cognitive impairment ...
Torbjörn Bäckström   +4 more
wiley   +1 more source

Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients

open access: yesDisease Markers, Volume 2023, Issue 1, 2023., 2023
Objective. Patients with cirrhosis and splenomegaly often have coagulation dysfunction which affects treatment and prognosis. This study explores the status, grading, and treatment strategies of coagulation dysfunction in patients with liver cirrhosis and splenomegaly. Methods.
Yunfu Lv   +7 more
wiley   +1 more source

A Challenging Case of Refractory Hepatic Encephalopathy in a Postliver Retransplant Patient with Thrombosed Portal Vein: A Shunt for a Shunt

open access: yesCase Reports in Hepatology, Volume 2023, Issue 1, 2023., 2023
Hepatic encephalopathy (HE) is a frequent and serious complication of chronic liver disease. The mechanism of hepatic encephalopathy is not entirely clear. Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portal‐systemic blood shunting.
Fady Salama   +4 more
wiley   +1 more source

A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement

open access: yesPortal Hypertension &Cirrhosis, Volume 1, Issue 2, Page 133-144, September 2022., 2022
Prognostic tools for survival prediction and risk stratification after transjugular intrahepatic portosystemic shunt placement. Abstract Patient prognosis after transjugular intrahepatic portosystemic shunt (TIPS) placement is relatively poor and highly heterogeneous; therefore, a prognostic scoring system is essential for survival prediction and risk ...
Chongtu Yang, Bin Xiong
wiley   +1 more source

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

open access: yesThe Journal of Clinical Pharmacology, Volume 62, Issue 6, Page 812-822, June 2022., 2022
Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50‐mg
Yan Xu   +13 more
wiley   +1 more source

Late Bleeding Episodes Following Intestinal Transplantation

open access: yesJPGN Reports, Volume 3, Issue 2, May 2022., 2022
Ectopic varices have been reported in 5% of children presenting with variceal bleeding and are defined as portosystemic venous collaterals occurring anywhere in the abdomen except in the cardioesophageal region. The liver‐intestinal transplant or isolated liver‐intestinal transplant patient presenting several years post‐transplant with ectopic variceal
Harveen Singh   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy